Li et al. 50 reported that UTI pretreatment can significantly suppress LPS-induced ROS production by activating the nuclear translocation of Nrf2 via promotion of p62-associated Keap1 degradation and then inhibiting inflammation and oxidation. The gene discussed is KEAP1; the disease is bacterial urinary tract infection.